Mesothelin, a novel immunotherapy target for triple negative breast cancer
| Autor: | Carl H. June, Michael Kalos, Hossein Borghaei, Liang-Chuan Wang, Paul J. Zhang, Ben Selven, Jose R. Conejo-Garcia, Hongtao Zhang, Robert H. Vondeheide, Julia Tchou, Steven M. Albelda |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Adoptive cell transfer endocrine system diseases Receptor ErbB-2 T-Lymphocytes medicine.medical_treatment T cell Breast Neoplasms GPI-Linked Proteins Article Targeted therapy Cohort Studies Breast cancer Antigens Neoplasm Transduction Genetic Cell Line Tumor Internal medicine medicine Humans Mesothelin Triple-negative breast cancer biology business.industry Immunotherapy medicine.disease Adoptive Transfer medicine.anatomical_structure Receptors Estrogen biology.protein Female Receptors Progesterone business Ovarian cancer |
| Zdroj: | Breast Cancer Research and Treatment. 133:799-804 |
| ISSN: | 1573-7217 0167-6806 |
| Popis: | Mesothelin is a cell-surface glycoprotein present on mesothelial cells and elicits T cell responses in a variety of cancers including pancreatic, biliary and ovarian cancer. Breast cancer is not known to express mesothelin. We postulated that mesothelin may be a unique tumor-associated antigen in triple negative breast cancer (TNBC), a less common breast cancer subtype which may have been under-represented in prior studies that characterized mesothelin expression. Therefore, we screened 99 primary breast cancer samples by immunohistochemistry analysis using formalin-fixed paraffin-embedded archival tumor tissues and confirmed that mesothelin was overexpressed in the majority of TNBC (67 %) but only rarely in |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink